Goldman Sachs Maintains Neutral on Protagonist Therapeutics, Raises Price Target to $95
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Richard Law maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Neutral and raises the price target from $65 to $95.
Goldman Sachs analyst Richard Law maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Neutral and raises the price target from $65 to $95.